Skip to main content
. Author manuscript; available in PMC: 2015 Apr 1.
Published in final edited form as: Hum Pathol. 2013 Nov 13;45(4):691–700. doi: 10.1016/j.humpath.2013.11.003

Figure 5.

Figure 5

Figure 5

IHC analysis of NLGN4X, NLGN1, SLITRK4, XRN2, HRASLS, TDO2, CRYM, Cx43/GJA1 and SHMT1 protein expression in LMS (A–N: primary LMS in left column, metastatic LMS in right column; ×200 magnification for all).

A–B: Higher Cx43/GJA1 expression in metastatic LMS

C–D: Higher CRYM expression in metastatic LMS

D–F: Higher HRASLS expression in primary LMS

G–H: Higher NLGN1 expression in primary LMS

I–J: Higher NLGN4X expression in primary LMS

K–L: Higher SLITRK4 expression in primary LMS

M–N: Higher TDO2 expression in metastatic LMS

O: SHMT1 in primary LMS

P: XRN2 in primary LMS